Goldman Sachs Group set a GBX 4,080 ($53.15) price target on AstraZeneca (LON:AZN) in a research report released on Wednesday. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.
AZN has been the subject of several other research reports. Citigroup reissued a buy rating on shares of AstraZeneca in a research note on Thursday, June 28th. UBS Group reissued a neutral rating and issued a GBX 5,900 ($76.85) price target on shares of AstraZeneca in a research note on Tuesday. Credit Suisse Group set a GBX 5,900 ($76.85) price target on shares of AstraZeneca and gave the company a buy rating in a research note on Friday, July 27th. Shore Capital reissued a hold rating on shares of AstraZeneca in a research note on Monday. Finally, Barclays reissued an overweight rating on shares of AstraZeneca in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of GBX 5,689.45 ($74.11).
Shares of LON AZN opened at GBX 5,918 ($77.09) on Wednesday. AstraZeneca has a 12-month low of GBX 4,260 ($55.49) and a 12-month high of GBX 5,520 ($71.90).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: How to Use a Moving Average for Trading
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.